Exelixis, Inc. (NASDAQ:EXEL) Shares Sold by GSA Capital Partners LLP

GSA Capital Partners LLP cut its stake in Exelixis, Inc. (NASDAQ:EXEL) by 81.9% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 11,708 shares of the biotechnology company’s stock after selling 52,983 shares during the quarter. GSA Capital Partners LLP’s holdings in Exelixis were worth $304,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of EXEL. V Square Quantitative Management LLC acquired a new position in shares of Exelixis during the 3rd quarter worth approximately $30,000. Park Place Capital Corp acquired a new position in shares of Exelixis during the 2nd quarter worth approximately $45,000. GAMMA Investing LLC raised its stake in shares of Exelixis by 107.9% during the 2nd quarter. GAMMA Investing LLC now owns 2,006 shares of the biotechnology company’s stock worth $45,000 after buying an additional 1,041 shares during the period. EntryPoint Capital LLC raised its stake in shares of Exelixis by 537.2% during the 1st quarter. EntryPoint Capital LLC now owns 2,071 shares of the biotechnology company’s stock worth $49,000 after buying an additional 1,746 shares during the period. Finally, Capital Performance Advisors LLP acquired a new position in shares of Exelixis during the 3rd quarter worth approximately $61,000. 85.27% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

EXEL has been the subject of several recent research reports. Piper Sandler increased their price objective on Exelixis from $33.00 to $36.00 and gave the company an “overweight” rating in a research note on Wednesday, October 30th. JMP Securities restated a “market outperform” rating and issued a $29.00 target price on shares of Exelixis in a report on Friday, October 11th. UBS Group assumed coverage on Exelixis in a report on Thursday, September 19th. They issued a “neutral” rating and a $30.00 target price for the company. Stifel Nicolaus upped their target price on Exelixis from $26.00 to $30.00 and gave the company a “hold” rating in a report on Wednesday, October 16th. Finally, The Goldman Sachs Group upgraded Exelixis to a “strong sell” rating in a report on Tuesday, October 15th. One analyst has rated the stock with a sell rating, five have given a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $31.44.

Insiders Place Their Bets

In related news, EVP Jeffrey Hessekiel sold 20,000 shares of the business’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $25.79, for a total transaction of $515,800.00. Following the sale, the executive vice president now owns 630,325 shares of the company’s stock, valued at approximately $16,256,081.75. The trade was a 3.08 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director George Poste sold 30,000 shares of the business’s stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $34.00, for a total transaction of $1,020,000.00. Following the sale, the director now directly owns 169,020 shares in the company, valued at approximately $5,746,680. This represents a 15.07 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 289,736 shares of company stock valued at $9,471,510. Insiders own 2.85% of the company’s stock.

Exelixis Stock Performance

Shares of Exelixis stock opened at $35.61 on Friday. Exelixis, Inc. has a 1 year low of $19.20 and a 1 year high of $36.60. The company has a market capitalization of $10.17 billion, a P/E ratio of 22.83, a PEG ratio of 0.87 and a beta of 0.51. The company’s fifty day moving average is $29.90 and its two-hundred day moving average is $25.57.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings data on Tuesday, October 29th. The biotechnology company reported $0.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.36 by $0.04. Exelixis had a net margin of 22.43% and a return on equity of 20.99%. The company had revenue of $539.50 million for the quarter, compared to the consensus estimate of $490.31 million. During the same period last year, the firm posted $0.10 EPS. Exelixis’s revenue for the quarter was up 14.3% on a year-over-year basis. As a group, equities analysts expect that Exelixis, Inc. will post 1.68 earnings per share for the current year.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.